Ozemback
Market

The business of peptides and GLP-1s: pricing, supply and who captures the money

Follow the money and most of the confusion resolves. This desk covers what these drugs cost and why, who pays, how shortages get manufactured and unmanufactured, and which intermediaries capture the margin between a manufacturer and a patient.

Shortages, savings cards and coverage decisions are not weather. They are commercial choices, made by identifiable parties, for reasons that can be reported.

10 articles in this desk
Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer